en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
1/2010
vol. 48
 
Share:
Share:
more
 
 
abstract:
Short communication

Prevention of tuberculosis in patients treated with tumour necrosis factor antagonists

Maria Korzeniewska-Koseła

Reumatologia 2010; 48, 1: 4-13
Online publish date: 2010/04/09
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Tumour necrosis factor inhibition increases the risk of tuberculosis. Active tuberculosis should be excluded and screening for latent tuberculosis infection should be done before commencement of treatment with tumour necrosis factor antagonists. Chest radiography and interferon-γ-release assay (IGRA) should be performed; medical history to screen for TB risk factors should be taken. IGRA use will help to reduce over-use and under-use of preventive treatment in candidates for TNF antagonist therapy. If a patient is diagnosed with latent TB infection, chemopreventive treatment should be introduced.
keywords:

TNF antagonists, tuberculosis, latent tuberculosis infection, chemoprophylaxis







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.